Similar Items: EGFR Mutations and Recurrence Outcomes in Resected Non‐Small Cell Lung Cancer: An Updated 2015–2025 Systematic Review and Meta‐Analysis
- MET Dependence Oversteps EGFR Dependence via Balancing Dimerization of the Receptor Tyrosine Kinases in Osimertinib‐Resistant MET‐Amplified, EGFR‐Mutated Non‐Small Cell Lung Cancer
- An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non‐Small‐Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib
- Acquired BRAF-AGK Fusion Following Osimertinib Plus Savolitinib in EGFR-Mutated MET-Amplified Non-Small-Cell Lung Cancer: Durable Response to Gefitinib and Trametinib in a Case Report
- Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR‐Mutated Advanced NSCLC: The Impact of Post‐Progression Management
- Analyzing the Influence of Surgical Sequence on Perioperative Circulating Tumor Cells in Patients with Resectable Non-Small Cell Lung Cancer
- Impact of Thyroid Transcription Factor‐1 Expression on Outcomes of Platinum‐Based Chemoimmunotherapy in Advanced or Recurrent Non‐Squamous Non‐Small Cell Lung Cancer